Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297708 | 0.83 | ESR2 (0.46) | MMP2 | |
| SCHEMBL10452224 | 0.75 | PTGS2 (0.46) | PTGS2 | |
| SCHEMBL2181909 | 0.75 | ENPP2 (0.47) | MMP2 | |
| SCHEMBL6300169 | 0.73 | LMNA (0.41) | — | |
| SCHEMBL2171082 | 0.72 | CA12 (0.47) | PTGS2 | |
| SCHEMBL6777687 | 0.72 | CYP1A2 (0.50) | — | |
| SCHEMBL28568618 | 0.70 | CA12 (0.51) | PTGS2 | |
| SCHEMBL2177479 | 0.70 | ENPP2 (0.48) | PTGS2 | |
| SCHEMBL1893515 | 0.70 | MMP2 (0.40) | MMP2 | |
| SCHEMBL7567240 | 0.69 | CA12 (0.64) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003018135-A1 | METHOD OF USING 5-(ARYLSULFONYL)-,5-(ARYLSULFINYL), AND 5-(ARYLSULFANYL)-THIAZOLIDINE-2,4-DIONES FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | FNTB, FNTA, TST | MMP2 1973/4885PTGS2 1687/4885 |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | FNTB, FNTA, NAT1 | MMP2 1688/4885PTGS2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.